{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:29:53Z","timestamp":1780723793435,"version":"3.54.1"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG-2019-22891"],"award-info":[{"award-number":["IG-2019-22891"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["813343"],"award-info":[{"award-number":["813343"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Virus-Like Particles (VLPs) are nanostructures that share conformation and self-assembly properties with viruses, but lack a viral genome and therefore the infectious capacity. In this study, we produced VLPs by co-expression of VSV glycoprotein (VSV-G) and HIV structural proteins (Gag, Pol) that incorporated a strong sequence-optimized 5\u2019ppp-RNA RIG-I agonist, termed M8. Treatment of target cells with VLPs-M8 generated an antiviral state that conferred resistance against multiple viruses. Interestingly, treatment with VLPs-M8 also elicited a therapeutic effect by inhibiting ongoing viral replication in previously infected cells. Finally, the expression of SARS-CoV-2 Spike glycoprotein on the VLP surface retargeted VLPs to ACE2 expressing cells, thus selectively blocking viral infection in permissive cells. These results highlight the potential of VLPs-M8 as a therapeutic and prophylactic vaccine platform. Overall, these observations indicate that the modification of VLP surface glycoproteins and the incorporation of nucleic acids or therapeutic drugs, will permit modulation of particle tropism, direct specific innate and adaptive immune responses in target tissues, and boost immunogenicity while minimizing off-target effects.<\/jats:p>","DOI":"10.3389\/fcimb.2022.1079926","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T07:53:18Z","timestamp":1671004398000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Virus-like particle \u2013 mediated delivery of the RIG-I agonist M8 induces a type I interferon response and protects cells against viral infection"],"prefix":"10.3389","volume":"12","author":[{"given":"Enrico","family":"Palermo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalini","family":"Alexandridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Di Carlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Muscolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hiscott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2022.02.002","article-title":"The coronavirus pandemic - 2022: Viruses, variants & vaccines","volume":"63","author":"Alexandridi","year":"2022","journal-title":"Cytokine Growth Factor Rev."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3791\/54041","article-title":"Expression and purification of virus-like particles for vaccination","author":"Arevalo","year":"2016","journal-title":"J. Vis. Exp"},{"key":"B3","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","article-title":"Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins","volume":"185","author":"Banskota","year":"2022","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","first-page":"10612","DOI":"10.1128\/JVI.01526-15","article-title":"Enhanced influenza virus-like particle vaccination with a structurally optimized RIG-I agonist as adjuvant","volume":"89","author":"Beljanski","year":"2015","journal-title":"J. Virol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.chom.2020.06.021","article-title":"Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2","volume":"28","author":"Case","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s00262-019-02380-2","article-title":"An optimized retinoic acid-inducible gene I agonist M8 induces immunogenic cell death markers in human cancer cells and dendritic cell activation","volume":"68","author":"Castiello","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"7367","DOI":"10.1007\/s00253-019-10038-3","article-title":"Production of hiv-1-Based virus-like particles for vaccination: Achievements and limits","volume":"103","author":"Cervera","year":"2019","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202152447","article-title":"Inclusion of cgamp within virus-like particle vaccines enhances their immunogenicity","volume":"22","author":"Chauveau","year":"2021","journal-title":"EMBO Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.molcel.2019.07.016","article-title":"N6-methyladenosine modification controls circular rna immunity","volume":"76","author":"Chen","year":"2019","journal-title":"Mol. Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"8011","DOI":"10.1128\/JVI.00845-15","article-title":"Sequence-specific modifications enhance the broad-spectrum antiviral response activated by rig-I agonists","volume":"89","author":"Chiang","year":"2015","journal-title":"J. Virol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.clim.2017.08.004","article-title":"Adjuvant formulations for virus-like particle (Vlp) based vaccines","volume":"183","author":"Cimica","year":"2017","journal-title":"Clin. Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.molimm.2004.06.028","article-title":"Recombinant hiv-1 Pr55gag virus-like particles: Potent stimulators of innate and acquired immune responses","volume":"42","author":"Deml","year":"2005","journal-title":"Mol. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"As04, an aluminum salt- and Tlr4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J. Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1099\/0022-1317-43-1-247","article-title":"Regulation of the interferon system: Evidence that vero cells have a genetic defect in interferon production","volume":"43","author":"Emeny","year":"1979","journal-title":"J. Gen. Virol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01551-20","article-title":"Dengue virus targets Nrf2 for Ns2b3-mediated degradation leading to enhanced oxidative stress and viral replication","volume":"94","author":"Ferrari","year":"2020","journal-title":"J. Virol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"7306","DOI":"10.1073\/pnas.1214441110","article-title":"Ldl receptor and its family members serve as the cellular receptors for vesicular stomatitis virus","volume":"110","author":"Finkelshtein","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1021\/mp3003368","article-title":"Ms2 viruslike particles: A robust, semisynthetic targeted drug delivery platform","volume":"10","author":"Galaway","year":"2012","journal-title":"Mol. Pharmaceutics"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00592","article-title":"Immunogenicity of a virus-Like-Particle vaccine containing multiple antigenic epitopes of toxoplasma gondii against acute and chronic toxoplasmosis in mice","volume":"10","author":"Guo","year":"2019","journal-title":"Front. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.it.2016.07.001","article-title":"Triggering intracellular receptors for vaccine adjuvantation","volume":"37","author":"Gutjahr","year":"2016","journal-title":"Trends In Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ebiom.2019.02.056","article-title":"Rig-I activating immunostimulatory rna boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade","volume":"41","author":"Heidegger","year":"2019","journal-title":"Ebiomedicine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aau8943","article-title":"Rig-I activation is critical for responsiveness to checkpoint blockade","volume":"4","author":"Heidegger","year":"2019","journal-title":"Sci. Immunol."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.832394","article-title":"The role of cytokines and chemokines in severe acute respiratory syndrome coronavirus 2 infections","volume":"13","author":"Hsu","year":"2022","journal-title":"Front. Immunol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005754","article-title":"Rig-I signaling is critical for efficient polyfunctional T cell responses during influenza virus infection","volume":"12","author":"Kandasamy","year":"2016","journal-title":"PloS Pathog."},{"key":"B25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jbiotec.2011.06.030","article-title":"Cell selective targeting of a simian virus 40 virus-like particle conjugated to epidermal growth factor","volume":"155","author":"Kitai","year":"2011","journal-title":"J. Of Biotechnol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1128\/JCM.43.7.3267-3272.2005","article-title":"Flow cytometry-based assay for titrating dengue virus","volume":"43","author":"Lambeth","year":"2005","journal-title":"J. Clin. Microbiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0025722","DOI":"10.1128\/jvi.00257-22","article-title":"A system based on novel parainfluenza virus Piv5-l for efficient gene delivery of b-lymphoma cells","volume":"96","author":"Liu","year":"2022","journal-title":"J. Of Virol."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.997875","article-title":"How promising are hiv-1-Based virus-like particles for medical applications","volume":"12","author":"Martins","year":"2022","journal-title":"Front. In Cell. And Infect. Microbiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1016\/j.vaccine.2013.02.042","article-title":"Hepatitis b virus-like particles access major histocompatibility class I and ii antigen presentation pathways in primary dendritic cells","volume":"31","author":"Moffat","year":"2013","journal-title":"Vaccine"},{"key":"B30","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/s41423-022-00897-8","article-title":"Virus-like particle vaccinology, from bench to bedside","volume":"19","author":"Mohsen","year":"2022","journal-title":"Cell Mol. Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/vaccines6030037","article-title":"Interaction of viral capsid-derived virus-like particles (Vlps) with the innate immune system","volume":"6","author":"Mohsen","year":"2018","journal-title":"Vaccines (Basel)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus-like particle (Vlp)-based vaccines","volume":"34","author":"Mohsen","year":"2017","journal-title":"Semin. Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"6753","DOI":"10.1073\/pnas.1131929100","article-title":"Immunization with hepatitis c virus-like particles protects mice from recombinant hepatitis c virus-vaccinia infection","volume":"100","author":"Murata","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B34","doi-asserted-by":"publisher","first-page":"14981","DOI":"10.1073\/pnas.0803988105","article-title":"Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis","volume":"105","author":"Nguy\u00ean","year":"2008","journal-title":"Proc. Of Natl. Acad. Of Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0966-842X(03)00208-7","article-title":"Virus-like particles as immunogens","volume":"11","author":"Noad","year":"2003","journal-title":"Trends Microbiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1128\/JVI.03114-13","article-title":"Inhibition of dengue and chikungunya virus infections by rig-I-Mediated type I interferon-independent stimulation of the innate antiviral response","volume":"88","author":"Olagnier","year":"2014","journal-title":"J. Virol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41423-021-00809-2","article-title":"Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for covid-19 in nonhuman primates","volume":"19","author":"Pillet","year":"2022","journal-title":"Cell Mol. Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1002\/cbic.201100469","article-title":"Cell targeting with hybrid q\u03b2 virus-like particles displaying epidermal growth factor","volume":"12","author":"Pokorski","year":"2011","journal-title":"Chembiochem"},{"key":"B39","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat. Rev. Drug Discovery"},{"key":"B40","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41577-020-0288-3","article-title":"Rig-I-Like receptors: Their regulation and roles in rna sensing","volume":"20","author":"Rehwinkel","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/btm2.10049","article-title":"Virus-like particles: Next-generation nanoparticles for targeted therapeutic delivery","volume":"2","author":"Rohovie","year":"2017","journal-title":"Bioeng Transl. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1586\/erv.10.115","article-title":"Virus-like particles in vaccine development","volume":"9","author":"Roldao","year":"2010","journal-title":"Expert Rev. Vaccines"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006032","article-title":"A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets","volume":"4","author":"Ross","year":"2009","journal-title":"PloS One"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1158\/1940-6207.CAPR-13-0203","article-title":"Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica vaccine trial","volume":"6","author":"Safaeian","year":"2013","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41467-018-08265-9","article-title":"Efficient oral vaccination by bioengineering virus-like particles with protozoan surface proteins","volume":"10","author":"Serradell","year":"2019","journal-title":"Nat. Commun."},{"key":"B46","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nri3488","article-title":"Applications of nanotechnology for immunology","volume":"13","author":"Smith","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000757","article-title":"Ips-1 is essential for the control of West Nile virus infection and immunity","volume":"6","author":"Suthar","year":"2010","journal-title":"PloS Pathog."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1126\/science.abl6184","article-title":"Rapid assessment of sars-Cov-2-Evolved variants using virus-like particles","volume":"374","author":"Syed","year":"2021","journal-title":"Science"},{"key":"B49","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.it.2015.12.003","article-title":"Integration of innate immune signaling","volume":"37","author":"Thaiss","year":"2016","journal-title":"Trends Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3390\/vaccines10020227","article-title":"Virus-like particles as preventive and therapeutic cancer vaccines","volume":"10","author":"Tornesello","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B51","volume-title":"Draft landscape of covid-19 candidate vaccines","year":"2022"},{"key":"B52","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/icb.2010.161","article-title":"Cross-presentation of epitopes on virus-like particles Via the mhc I receptor recycling pathway","volume":"89","author":"Win","year":"2011","journal-title":"Immunol. Cell Biol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"7679","DOI":"10.1038\/s41598-017-08247-9","article-title":"Virus-like particles that display zika virus envelope protein domain iii induce potent neutralizing immune responses in mice","volume":"7","author":"Yang","year":"2017","journal-title":"Sci. Rep."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01379","article-title":"Rig-I-Like receptors as novel targets for pan-antivirals and vaccine adjuvants against emerging and re-emerging viral infections","volume":"9","author":"Yong","year":"2018","journal-title":"Front. Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"5499","DOI":"10.4049\/jimmunol.1400065","article-title":"Viral particles drive rapid differentiation of memory b cells into secondary plasma cells producing increased levels of antibodies","volume":"192","author":"Zabel","year":"2014","journal-title":"J. Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.it.2016.12.004","article-title":"Crosstalk between cytoplasmic rig-I and sting sensing pathways","volume":"38","author":"Zevini","year":"2017","journal-title":"Trends Immunol."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.910864","article-title":"Inhibition of glycolysis impairs retinoic acid-inducible gene I\u2013mediated antiviral responses in primary human dendritic cells","volume":"12","author":"Zevini","year":"2022","journal-title":"Front. In Cell. And Infect. Microbiol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3390\/vaccines9040395","article-title":"Development of a vaccine against sars-Cov-2 based on the receptor-binding domain displayed on virus-like particles","volume":"9","author":"Zha","year":"2021","journal-title":"Vaccines"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.1079926\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T07:53:21Z","timestamp":1671004401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.1079926\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":58,"alternative-id":["10.3389\/fcimb.2022.1079926"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2022.1079926","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,14]]},"article-number":"1079926"}}